# Hypoxia-driven metastatic progression in synovial sarcoma: insights from SYO-1 and SW982 models

**Authors:** Maria Fueth, Jannis Christoffel, Kamran Harati, Felix Reinkemeier, Sonja Verena Schmidt, Marius Drysch, Flemming Puscz, Jannik Hinzmann, Tom Alexander Huyghebaert, Alexander Fiedler, Marcus Lehnhardt, Christoph Wallner, Yonca Steubing

PMC · DOI: 10.1186/s12885-025-15125-5 · BMC Cancer · 2025-10-31

## TL;DR

This study explores how low oxygen levels (hypoxia) promote the spread of synovial sarcoma, a rare cancer, using two cell line models and identifying key genes involved in metastasis.

## Contribution

The study reveals that hypoxia enhances metastasis in synovial sarcoma, particularly in fusion-positive cells, through HIF-1α and related pathways.

## Key findings

- Hypoxia upregulates HIF-1α targets like CA9 and VEGF more strongly in fusion-positive SYO-1 cells compared to fusion-negative SW982 cells.
- Fusion-positive SYO-1 cells form more lung metastases in mice under hypoxia, showing perivascular clustering and intravasation.
- HIF-1α, CA9, and IGF2 expression correlate with metastatic capacity, while TGF-β1 decreases under hypoxia.

## Abstract

Synovial sarcoma (SS) is a rare but aggressive soft tissue malignancy characterized by a high rate of pulmonary metastasis and limited response to conventional therapies. Hypoxia, a common feature of tumor microenvironment, has been implicated in cancer progression, yet its specific contribution to metastatic dissemination in SS remains insufficiently characterized.

We investigated the effects of hypoxia on metastatic behavior in two SS cell lines: SYO-1 (SS18-SSX2 fusion-positive) and SW982 (fusion-negative). Cells were cultured under hypoxic (O₂ < 1%) and normoxic (21% O₂) conditions, followed by reoxygenation. Expression of hypoxia-responsive and metastasis-related genes (e.g., HIF-1α, CA9, VEGF, IGF2, ADM, YB-1, TGF-β1) was assessed via qRT-PCR. To evaluate in vivo metastatic potential, a lung colonization model was established by injecting pretreated cells into the tail veins of immunodeficient (NMRI nu/nu) mice.

Hypoxia significantly upregulated canonical HIF-1α targets in both cell lines, with SYO-1 showing stronger and more sustained induction, particularly of CA9 and VEGF. In vivo, SYO-1 cells formed significantly more micrometastatic lung lesions compared to SW982, with distinct perivascular clustering and signs of early intravasation. SW982 cells exhibited limited, diffuse infiltration and lower hypoxia-induced gene activation. These differences suggest that the SS18-SSX fusion may synergize with hypoxia signaling to enhance metastatic potential. Notably, HIF-1α, CA9, and IGF2 expression correlated with metastatic capacity, while TGF-β1 expression declined under hypoxia, indicating a dynamic regulation of prometastatic pathways.

Our findings demonstrate that hypoxia promotes SS metastasis through activation of HIF-1α and related pathways. Fusion-positive SS cells appear particularly responsive to hypoxic cues, suggesting that targeting hypoxia-induced signaling could be a promising strategy to inhibit metastasis in SS. These results provide mechanistic insight into SS progression and support the integration of hypoxia-targeted therapies into future treatment strategies.

## Linked entities

- **Genes:** HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091], CA9 (carbonic anhydrase 9) [NCBI Gene 768], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], IGF2 (insulin like growth factor 2) [NCBI Gene 3481], ADM (adrenomedullin) [NCBI Gene 133], YBX1 (Y-box binding protein 1) [NCBI Gene 4904], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040]
- **Diseases:** synovial sarcoma (MONDO:0010434)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** ADM (adrenomedullin) [NCBI Gene 133] {aka AM, PAMP}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, IGF2 (insulin like growth factor 2) [NCBI Gene 3481] {aka C11orf43, GRDF, IGF-II, PP9974, SRS3}, YBX1 (Y-box binding protein 1) [NCBI Gene 4904] {aka BP-8, CBF-A, CSDA2, CSDB, DBPB, EFI-A}, CA9 (carbonic anhydrase 9) [NCBI Gene 768] {aka CAIX, MN}, TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, SSX2 (SSX family member 2) [NCBI Gene 6757] {aka CT5.2, CT5.2A, HD21, HOM-MEL-40, SSX}, SS18 (SS18 subunit of BAF chromatin remodeling complex) [NCBI Gene 6760] {aka SMARCL1, SSXT, SYT}
- **Diseases:** SS (MESH:D013584), Hypoxia (MESH:D000860), lung (MESH:D008171), cancer (MESH:D009369), hypoxic (MESH:D002534), soft tissue malignancy (MESH:D012983), metastasis (MESH:D009362)
- **Chemicals:** O2 (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** SYO-1 — Homo sapiens (Human), Biphasic synovial sarcoma, Cancer cell line (CVCL_7146), SW982 — Homo sapiens (Human), Biphasic synovial sarcoma, Cancer cell line (CVCL_1734)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12577431/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12577431/full.md

## References

3 references — full list in the complete paper: https://tomesphere.com/paper/PMC12577431/full.md

---
Source: https://tomesphere.com/paper/PMC12577431